Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H22ClN3O3 |
| Molecular Weight | 447.913 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC=CC(NC(=O)C(=O)C2=C(C)N(CC3=CC=C(Cl)C=C3)C4=C2C=C(C)C=C4)=C1
InChI
InChIKey=RIKZRSJVZWKHNX-UHFFFAOYSA-N
InChI=1S/C25H22ClN3O3/c1-15-4-9-21-20(12-15)23(16(2)29(21)14-17-5-7-18(26)8-6-17)24(30)25(31)28-19-10-11-27-22(13-19)32-3/h4-13H,14H2,1-3H3,(H,27,28,31)
| Molecular Formula | C25H22ClN3O3 |
| Molecular Weight | 447.913 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:19:43 GMT 2025
by
admin
on
Mon Mar 31 18:19:43 GMT 2025
|
| Record UNII |
ET9Q0750O6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
25143721
Created by
admin on Mon Mar 31 18:19:43 GMT 2025 , Edited by admin on Mon Mar 31 18:19:43 GMT 2025
|
PRIMARY | |||
|
ET9Q0750O6
Created by
admin on Mon Mar 31 18:19:43 GMT 2025 , Edited by admin on Mon Mar 31 18:19:43 GMT 2025
|
PRIMARY | |||
|
1006604-91-6
Created by
admin on Mon Mar 31 18:19:43 GMT 2025 , Edited by admin on Mon Mar 31 18:19:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
MM-433593 is a highly potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) with potential utility as an orally administered treatment of pain, inflammation, and other disorders. In this study, we investigated the metabolism and pharmacokinetics of MM-433593 in monkeys, and compared plasma and urine metabolites of this compound to the in vitro metabolites produced by monkey hepatocytes. Intravenous administration of MM-433593 to cynomolgus monkeys produced a rapid distribution phase and slower elimination phase with a mean systemic clearance rate of 8-11 mL/min/kg. Absolute oral bioavailability was determined to be 14-21% with maximum plasma concentrations reached 3 h (T max) following a 10 mg/kg oral dose. The average terminal half-life of MM-433593 was 17-20 h, and there were no qualitative sex differences in the metabolite profile of MM-433593. The major site of metabolism was oxidation of the methyl group at the five position of the indole ring, which was confirmed by chromatography and mass spectrometry comparison to a synthesized authentic standard.
|
||
|
ACTIVE MOIETY |
MM-433593 had been in phase I clinical trials by Ironwood for the treatment of pain. However, no recent development has been reported.
|
